Alithea Bio joins Berlin’s precision medicine ecosystem

We’re excited to announce that Alithea Bio is now officially part of Berlin’s thriving biotech community, with our laboratory established at BioCube on Campus Berlin-Buch — one of Europe’s leading life sciences campuses.

Berlin Partner für Wirtschaft und Technologie, the city’s official economic development agency, has recognized Alithea Bio as one of Berlin’s newest biotech arrivals — a milestone that reflects our commitment to building a serious scientific presence in the German capital. You can find our profile on page 37 of the Berlin Partner Annual Report 2025.

Berlin Partner supported our arrival through funding programme guidance, innovation financing advice, and introductions into Berlin’s biotech ecosystem. Their hands-on support made the transition into the Berlin market significantly smoother.

Berlin is home to world-class research institutions, a dense network of BioPharma companies, and one of Europe’s most active life sciences clusters — exactly the environment where Alithea Bio’s HLA peptidomics platform can have the greatest impact. Our work supporting BioPharma companies in target identification, neoantigen validation, and off-target toxicity prediction fits naturally into a city that is increasingly becoming a global hub for precision medicine and cancer immunotherapy.

We’re grateful to Berlin Partner, Campus Berlin-Buch, and the broader Berlin biotech community for the warm welcome. This is just the beginning.

 Learn more about Berlin Partner  Read the full Annual Report 2025  Learn more about Campus Berlin-Buch